Rituximab for connective tissue disease-associated interstitial lung disease
- PMID: 36375480
- DOI: 10.1016/S2213-2600(22)00356-3
Rituximab for connective tissue disease-associated interstitial lung disease
Erratum in
-
Correction to Lancet Respir Med 2023; 11: 3-4.Lancet Respir Med. 2023 Jan;11(1):e11. doi: 10.1016/S2213-2600(22)00484-2. Epub 2022 Nov 30. Lancet Respir Med. 2023. PMID: 36462508 No abstract available.
Conflict of interest statement
MS has received payments or honoraria for lectures or presentations from BMS, Pfizer, and Boehringer-Ingelheim; and fees for participation on advisory boards from BMS, Lilly, Amgen, Janssen, Boehringer-Ingelheim, and Celltrion. CS declares participation on an advisory board for Lilly. AM has received payments or honoraria for lectures or presentations from BMS, Lilly, and Boehringer-Ingelheim; and fees for participation on advisory boards from BMS, Lilly, and Boehringer-Ingelheim.
Comment on
-
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.Lancet Respir Med. 2023 Jan;11(1):45-54. doi: 10.1016/S2213-2600(22)00359-9. Epub 2022 Nov 11. Lancet Respir Med. 2023. PMID: 36375479 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
